CSAClinical-Stage Asset Intelligence
Catalyst calendar Get the data
Home / Ionis Pharmaceuticals INC (IONS) / olezarsen
Forward catalyst · IONS

olezarsen

Sponsor Ionis Pharmaceuticals INC · listed as IONS

READOUT Phase 3 Confidence: medium Source: clinicaltrials

olezarsen is a drug asset sponsored by Ionis Pharmaceuticals INC, listed as IONS. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Mar 2027 (month precision, medium confidence), tied to trial NCT05681351. That trial is in Phase 3 and currently active not recruiting, studying Severe Hypertriglyceridemia.

Next catalyst

Event typeREADOUT
Expected date2027-03-31
As disclosedMar 2027
Date precisionmonth
Confidencemedium
Verify at source →

Trial & sponsor

Trial (NCT)NCT05681351
PhasePHASE3
StatusACTIVE_NOT_RECRUITING
Lead sponsorIonis Pharmaceuticals, Inc.
Listed asIONS
Condition(s)Severe Hypertriglyceridemia
!

Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.

This page is one record from the free CSA sample. The full snapshot covers active, industry-sponsored Phase 3 trials in cardiometabolic, oncology and immunology. Every forward catalyst carries its date, confidence grade and source link, and is linked to its sponsor's ticker when the sponsor is a listed company.

Get the full dataset — $499 →   More IONS catalysts

Related catalysts and sponsor